The role of artificial intelligence in the management of liver diseases.
algorithms
artificial intelligence (AI)
hepatitis C virus (HCV)
hepatocellular carcinoma (HCC)
machine learning (ML)
Journal
The Kaohsiung journal of medical sciences
ISSN: 2410-8650
Titre abrégé: Kaohsiung J Med Sci
Pays: China (Republic : 1949- )
ID NLM: 100960562
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
revised:
24
09
2024
received:
11
09
2024
accepted:
24
09
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
23
10
2024
Statut:
aheadofprint
Résumé
Universal neonatal hepatitis B virus (HBV) vaccination and the advent of direct-acting antivirals (DAA) against hepatitis C virus (HCV) have reshaped the epidemiology of chronic liver diseases. However, some aspects of the management of chronic liver diseases remain unresolved. Nucleotide analogs can achieve sustained HBV DNA suppression but rarely lead to a functional cure. Despite the high efficacy of DAAs, successful antiviral therapy does not eliminate the risk of hepatocellular carcinoma (HCC), highlighted the need for cost-effective identification of high-risk populations for HCC surveillance and tailored HCC treatment strategies for these populations. The accessibility of high-throughput genomic data has accelerated the development of precision medicine, and the emergence of artificial intelligence (AI) has led to a new era of precision medicine. AI can learn from complex, non-linear data and identify hidden patterns within real-world datasets. The combination of AI and multi-omics approaches can facilitate disease diagnosis, biomarker discovery, and the prediction of treatment efficacy and prognosis. AI algorithms have been implemented in various aspects, including non-invasive tests, predictive models, image diagnosis, and the interpretation of histopathology findings. AI can support clinicians in decision-making, alleviate clinical burdens, and curtail healthcare expenses. In this review, we introduce the fundamental concepts of machine learning and review the role of AI in the management of chronic liver diseases.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Sun Yat-sen University
ID : MOHW112-TDU-B-221-124007
Organisme : National Sun Yat-sen University
ID : NSTC 112-2321-B-001-006
Informations de copyright
© 2024 The Author(s). The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University.
Références
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858.
Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650–2666.
Forbes C, Lavoie L, Satram S, Shen L, Thanawala V, Arizpe A, et al. Global importance of new treatment strategies to efforts to control hepatitis B virus. Expert Rev Anti Infect Ther. 2023;21:847–862.
Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, et al. Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: a real‐world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021;41:1265–1277.
Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct‐acting antiviral HCV therapy: a systematic review, meta‐analyses, and meta‐regression. J Hepatol. 2017;67:1204–1212.
Huang CF, Yu ML. Unmet needs of chronic hepatitis C in the era of direct‐acting antiviral therapy. Clin Mol Hepatol. 2020;26:251–260.
Huang CF, Awad MH, Gal‐Tanamy M, Yu ML. Unmet needs in the post‐DAA era: the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication. Clin Mol Hepatol. 2024;30:326–344.
Nam D, Chapiro J, Paradis V, Seraphin TP, Kather JN. Artificial intelligence in liver diseases: improving diagnostics, prognostics and response prediction. JHEP Rep. 2022;4:100443.
Cao JS, Lu ZY, Chen MY, Zhang B, Juengpanich S, Hu JH, et al. Artificial intelligence in gastroenterology and hepatology: status and challenges. World J Gastroenterol. 2021;27:1664–1690.
Ng S, Masarone S, Watson D, Barnes MR. The benefits and pitfalls of machine learning for biomarker discovery. Cell Tissue Res. 2023;394:17–31.
Ahn JC, Connell A, Simonetto DA, Hughes C, Shah VH. Application of artificial intelligence for the diagnosis and treatment of liver diseases. Hepatology. 2021;73:2546–2563.
Castane H, Baiges‐Gaya G, Hernandez‐Aguilera A, Rodriguez‐Tomas E, Fernandez‐Arroyo S, Herrero P, et al. Coupling machine learning and lipidomics as a tool to investigate metabolic dysfunction‐associated fatty liver disease. A general overview biomolecules. Biomolecules. 2021;11:11.
Rashidi HH, Tran N, Albahra S, Dang LT. Machine learning in health care and laboratory medicine: general overview of supervised learning and auto‐ML. Int J Lab Hematol. 2021;43(Suppl 1):15–22.
Al Fryan LH, Shomo MI, Alazzam MB, Rahman MA. Processing decision tree data using internet of things (IoT) and artificial intelligence technologies with special reference to medical application. Biomed Res Int. 2022;2022:8626234–8626239.
Pruneski JA, Pareek A, Kunze KN, Martin RK, Karlsson J, Oeding JF, et al. Supervised machine learning and associated algorithms: applications in orthopedic surgery. Knee Surg Sports Traumatol Arthrosc. 2023;31:1196–1202.
Aydin Temel F, Cagcag Yolcu O, Turan NG. Artificial intelligence and machine learning approaches in composting process: a review. Bioresour Technol. 2023;370:128539.
Blanchet L, Vitale R, van Vorstenbosch R, Stavropoulos G, Pender J, Jonkers D, et al. Constructing bi‐plots for random forest: tutorial. Anal Chim Acta. 2020;1131:146–155.
Mayr A, Binder H, Gefeller O, Schmid M. The evolution of boosting algorithms. From machine learning to statistical modelling. Methods Inf Med. 2014;53:419–427.
Ilboudo WEL, Kobayashi T, Sugimoto K. Robust stochastic gradient descent with student‐t distribution based first‐order momentum. IEEE Trans Neural Netw Learn Syst. 2022;33:1324–1337.
Albahra S, Gorbett T, Robertson S, D'Aleo G, Kumar SVS, Ockunzzi S, et al. Artificial intelligence and machine learning overview in pathology & laboratory medicine: a general review of data preprocessing and basic supervised concepts. Semin Diagn Pathol. 2023;40:71–87.
Cao B, Zhang KC, Wei B, Chen L. Status quo and future prospects of artificial neural network from the perspective of gastroenterologists. World J Gastroenterol. 2021;27:2681–2709.
Balsano C, Alisi A, Brunetto MR, Invernizzi P, Burra P, Piscaglia F, et al. The application of artificial intelligence in hepatology: a systematic review. Dig Liver Dis. 2022;54:299–308.
Mutasa S, Sun S, Ha R. Understanding artificial intelligence based radiology studies: CNN architecture. Clin Imaging. 2021;80:72–76.
Durstewitz D, Koppe G, Thurm MI. Reconstructing computational system dynamics from neural data with recurrent neural networks. Nat Rev Neurosci. 2023;24:693–710.
Juluru K, Shih HH, Keshava Murthy KN, Elnajjar P. Bag‐of‐words technique in natural language processing: a primer for radiologists. Radiographics. 2021;41:1420–1426.
Nehme F, Feldman K. Evolving role and future directions of natural language processing in gastroenterology. Dig Dis Sci. 2021;66:29–40.
Cabot JH, Ross EG. Evaluating prediction model performance. Surgery. 2023;174:723–726.
Friedman SL, Pinzani M. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology. 2022;75:473–488.
Doyle OM, Leavitt N, Rigg JA. Finding undiagnosed patients with hepatitis C infection: an application of artificial intelligence to patient claims data. Sci Rep. 2020;10:10521.
Hashem S, Esmat G, Elakel W, Habashy S, Raouf SA, Elhefnawi M, et al. Comparison of machine learning approaches for prediction of advanced liver fibrosis in chronic hepatitis C patients. IEEE/ACM Trans Comput Biol Bioinform. 2018;15:861–868.
Shousha HI, Awad AH, Omran DA, Elnegouly MM, Mabrouk M. Data mining and machine learning algorithms using IL28B genotype and biochemical markers best predicted advanced liver fibrosis in chronic hepatitis C. Jpn J Infect Dis. 2018;71:51–57.
Konerman MA, Zhang Y, Zhu J, Higgins PD, Lok AS, Waljee AK. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology. 2015;61:1832–1841.
Lu MY, Huang CF, Hung CH, Tai CM, Mo LR, Kuo HT, et al. Artificial intelligence predicts direct‐acting antivirals failure among hepatitis C virus patients: a nationwide hepatitis C virus registry program. Clin Mol Hepatol. 2024;30:64–79.
Lu MY, Yu ML. Correspondence on letter regarding "toward hepatitis C virus elimination using artificial intelligence". Clin Mol Hepatol. 2024;30:274–275.
Hsu PY, Liang PC, Chang WT, Lu MY, Wang WH, Chuang SC, et al. Artificial intelligence based on serum biomarkers predicts the efficacy of lenvatinib for unresectable hepatocellular carcinoma. Am J Cancer Res. 2022;12:5576–5588.
Abajian A, Murali N, Savic LJ, Laage‐Gaupp FM, Nezami N, Duncan JS, et al. Predicting treatment response to intra‐arterial therapies for hepatocellular carcinoma with the use of supervised machine learning—an artificial intelligence concept. J Vasc Interv Radiol. 2018;29:850–857.e1.
Lu MY, Liu TW, Liang PC, Huang CI, Tsai YS, Tsai PC, et al. Decision tree algorithm predicts hepatocellular carcinoma among chronic hepatitis C patients following viral eradication. Am J Cancer Res. 2023;13:190–203.
Ioannou GN, Tang W, Beste LA, Tincopa MA, Su GL, Van T, et al. Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis. JAMA Netw Open. 2020;3:e2015626.
Yasaka K, Akai H, Kunimatsu A, Abe O, Kiryu S. Liver fibrosis: deep convolutional neural network for staging by using Gadoxetic acid‐enhanced hepatobiliary phase MR images. Radiology. 2018;287:146–155.
Sato M, Kobayashi T, Soroida Y, Tanaka T, Nakatsuka T, Nakagawa H, et al. Development of novel deep multimodal representation learning‐based model for the differentiation of liver tumors on B‐mode ultrasound images. J Gastroenterol Hepatol. 2022;37:678–684.
Kim DW, Lee G, Kim SY, Ahn G, Lee JG, Lee SS, et al. Deep learning‐based algorithm to detect primary hepatic malignancy in multiphase CT of patients at high risk for HCC. Eur Radiol. 2021;31:7047–7057.
Kim J, Min JH, Kim SK, Shin SY, Lee MW. Detection of hepatocellular carcinoma in contrast‐enhanced magnetic resonance imaging using deep learning classifier: a multi‐center retrospective study. Sci Rep. 2020;10:9458.
Yasaka K, Akai H, Abe O, Kiryu S. Deep learning with convolutional neural network for differentiation of liver masses at dynamic contrast‐enhanced CT: a preliminary study. Radiology. 2018;286:887–896.
Cheng N, Ren Y, Zhou J, Zhang Y, Wang D, Zhang X, et al. Deep learning‐based classification of hepatocellular nodular lesions on whole‐slide histopathologic images. Gastroenterology. 2022;162:1948–1961 e1947.
Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108–113.
Chen Q, Xiao H, Gu Y, Weng Z, Wei L, Li B, et al. Deep learning for evaluation of microvascular invasion in hepatocellular carcinoma from tumor areas of histology images. Hepatol Int. 2022;16:590–602.
Saillard C, Schmauch B, Laifa O, Moarii M, Toldo S, Zaslavskiy M, et al. Predicting survival after hepatocellular carcinoma resection using deep learning on histological slides. Hepatology. 2020;72:2000–2013.
Harkus U, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Semin Cancer Biol. 2022;86:799–815.
Sangro B, Melero I, Wadhawan S, Finn RS, Abou‐Alfa GK, Cheng AL, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab‐treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73:1460–1469.
Haber PK, Castet F, Torres‐Martin M, Andreu‐Oller C, Puigvehi M, Miho M, et al. Molecular markers of response to anti‐PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology. 2023;164:72–88 e18.
Zeng Q, Klein C, Caruso S, Maille P, Laleh NG, Sommacale D, et al. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol. 2022;77:116–127.
Dhanasekaran R, Nault JC, Roberts LR, Zucman‐Rossi J. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy. Gastroenterology. 2019;156:492–509.
Wang H, Jiang Y, Li B, Cui Y, Li D, Li R. Single‐cell spatial analysis of tumor and immune microenvironment on whole‐slide image reveals hepatocellular carcinoma subtypes. Cancers (Basel). 2020;12:3562.
Bussmann N, Giudici P, Marinelli D, Papenbrock J. Explainable AI in Fintech risk management. Front Artif Intell. 2020;3:26.
Kleppe A, Skrede OJ, De Raedt S, Liestol K, Kerr DJ, Danielsen HE. Designing deep learning studies in cancer diagnostics. Nat Rev Cancer. 2021;21:199–211.
Waring J, Lindvall C, Umeton R. Automated machine learning: review of the state‐of‐the‐art and opportunities for healthcare. Artif Intell Med. 2020;104:101822.
Park H, Lo‐Ciganic WH, Huang J, Wu Y, Henry L, Peter J, et al. Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: an HCV‐TARGET analysis. Hepatology. 2022;76:483–491.
Audureau E, Carrat F, Layese R, Cagnot C, Asselah T, Guyader D, et al. Personalized surveillance for hepatocellular carcinoma in cirrhosis—using machine learning adapted to HCV status. J Hepatol. 2020;73:1434–1445.